BLCO logo

Bausch + Lomb Corporation Stock Price

NYSE:BLCO Community·US$5.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

BLCO Share Price Performance

US$14.32
-4.80 (-25.10%)
US$14.32
-4.80 (-25.10%)
Price US$14.32

BLCO Community Narratives

There are no narratives available yet.

Recent BLCO News & Updates

Bausch + Lomb: There Are Better Opportunities Out There (Rating Downgrade)

Sep 19

Bausch + Lomb (NYSE:BLCO) Use Of Debt Could Be Considered Risky

Jun 10
Bausch + Lomb (NYSE:BLCO) Use Of Debt Could Be Considered Risky

Bausch + Lomb Corporation Key Details

US$4.9b

Revenue

US$2.0b

Cost of Revenue

US$2.9b

Gross Profit

US$3.2b

Other Expenses

-US$273.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 29, 2025
Earnings per share (EPS)
-0.77
Gross Margin
59.68%
Net Profit Margin
-5.58%
Debt/Equity Ratio
76.2%

Bausch + Lomb Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with moderate growth potential.

0 Risks
3 Rewards

About BLCO

Founded
1853
Employees
13500
CEO
Brenton Saunders
WebsiteView website
www.bausch.com

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Canadian Market Performance

  • 7 Days: 0.4%
  • 3 Months: 10.0%
  • 1 Year: 21.2%
  • Year to Date: 19.9%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 21% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›